Kabra Drugs Intrinsic Value
KABRADG Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹41.80 | ₹33.44 - ₹50.16 | +39.6% | EPS: ₹1.90, Sector P/E: 22x |
| Book Value Method | asset | ₹20.83 | ₹18.75 - ₹22.91 | -30.4% | Book Value/Share: ₹10.42, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹48.33 | ₹43.50 - ₹53.16 | +61.4% | Revenue/Share: ₹24.17, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹20.83 | ₹18.75 - ₹22.91 | -30.4% | EBITDA: ₹5.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹12.16 | ₹10.94 - ₹13.38 | -59.4% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹29.36 | ₹26.42 - ₹32.30 | -1.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹23.33 | ₹21.00 - ₹25.66 | -22.1% | ROE: 16.0%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹20.83 | ₹18.75 - ₹22.91 | -30.4% | EPS: ₹1.90, BVPS: ₹10.42 |
Want to compare with current market value? Check KABRADG share price latest .
Valuation Comparison Chart
KABRADG Intrinsic Value Analysis
What is the intrinsic value of KABRADG?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Kabra Drugs (KABRADG) is ₹23.33 (median value). With the current market price of ₹29.94, this represents a -22.1% variance from our estimated fair value.
The valuation range spans from ₹12.16 to ₹48.33, indicating ₹12.16 - ₹48.33.
Is KABRADG undervalued or overvalued?
Based on our multi-method analysis, Kabra Drugs (KABRADG) appears to be trading above calculated value by approximately 22.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 16.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.32x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Kabra Drugs
Additional stock information and data for KABRADG
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-5 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |